Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 11:02 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: T2D Clear all
Completed Phase 4 Interventional Results available

Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2

NCT03782259
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Myocardial Fibrosis, Myocardial Inflammation
Interventions
dapagliflozin, Placebo
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
62 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 28, 2023 · Synced Sep 8, 2026, 11:02 AM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

mHealth Titration and Management

NCT03908762
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Diabetic Complication
Interventions
iSage App with connected glucometer, Magnet
Device · Behavioral
Lead sponsor
Amalgam Rx, Inc.
Industry
Eligibility
21 Years to 100 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 8, 2019 · Synced Sep 8, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study To Evaluate Safety And Efficacy Of Investigational Drug - PF04937319 In Patients With Type 2 Diabetes

NCT01475461
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Placebo, PF-04937319 - 3mg, PF-04937319 - 20mg, PF-04937319 - 50mg, PF-04937319 - 100mg, Sitagliptin - 100mg
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
345 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
24
States / cities
Anaheim, California • Los Angeles, California • Spring Valley, California + 18 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Sep 8, 2026, 11:02 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Dapagliflozin on Inflammation and Endothelial Function

NCT02608905
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Dapagliflozin, Placebo
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced Sep 8, 2026, 11:02 AM EDT
Completed Not applicable Interventional

CardioMetabolic Program Meets eHealth: Redesign and Evaluation for Optimal Reach and Impact

NCT02246400
View directory record Official record
Conditions
Obesity, Metabolic Syndrome, Pre-diabetes, Type 2 Diabetes, Cardiovascular Disease
Interventions
eCMP
Behavioral
Lead sponsor
Palo Alto Medical Foundation
Other
Eligibility
18 Years and older
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
1
States / cities
Burlingame, California
Source: ClinicalTrials.gov public record
Updated Jun 1, 2015 · Synced Sep 8, 2026, 11:02 AM EDT
Terminated Not applicable Interventional Results available

Safety Study of Using Symlin Alongside Insulin in a Multiple Injection Port

NCT00790699
View directory record Official record
Conditions
Type 1 Diabetes, Type 2 Diabetes
Interventions
I-PORT, standard injections
Device · Other
Lead sponsor
Texas Diabetes & Endocrinology, P.A.
Other
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Oct 19, 2020 · Synced Sep 8, 2026, 11:02 AM EDT
Completed Phase 2 Interventional Results available

Study To Understand Efficacy And Safety Of Investigational Agent (PF-04937319) Compared To Approved Agent (Glimepiride) In Patients With Diabetes On Metformin

NCT01517373
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Placebo, PF-04937319 10 mg, PF-04937319 50 mg, PF-04937319 100 mg, Glimepiride
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 70 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
23
States / cities
Roseville, California • San Diego, California • Walnut Creek, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jan 30, 2017 · Synced Sep 8, 2026, 11:02 AM EDT
Completed Not applicable Interventional

Acceptance and Commitment Therapy Principles for Diabetes Prevention

NCT05260983
View directory record Official record
Conditions
PreDiabetes, Diabetes Mellitus, Type 2, Diabetes, Diabetes type2
Interventions
Diabetes Prevention Education and Acceptance and Commitment Therapy, Diabetes Prevention Education Only
Behavioral
Lead sponsor
University of Oregon
Other
Eligibility
18 Years and older
Enrollment
301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
1
States / cities
Eugene, Oregon
Source: ClinicalTrials.gov public record
Updated Mar 1, 2022 · Synced Sep 8, 2026, 11:02 AM EDT
Recruiting Not applicable Interventional

Culturally Tailored Program for Food-Insecure Adults: SPICE-D

NCT07361341
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2D)
Interventions
Food Bundle Intervention
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 25, 2026 · Synced Sep 8, 2026, 11:02 AM EDT
Completed Phase 3 Interventional

Study Comparing Muraglitazar With Glimepiride in Type 2 Diabetics Who Are Not Controlled With Metformin Alone

NCT00095030
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
muraglitazar
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 70 Years
Enrollment
1,752 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
108
States / cities
Birmingham, Alabama • Mesa, Arizona • Phoenix, Arizona + 105 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2010 · Synced Sep 8, 2026, 11:02 AM EDT
Completed Not applicable Interventional

A Comprehensive Community Approach for Diabetes Prevention and Care for a Vulnerable Population in Galveston

NCT05097534
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
iDSMES, Standard of Care
Other
Lead sponsor
The University of Texas Medical Branch, Galveston
Other
Eligibility
13 Years to 84 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced Sep 8, 2026, 11:02 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Diabetes TeleCare Study

NCT00288132
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Intervention, Usual Care
Behavioral
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
21 Years and older
Enrollment
165 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2005 – 2008
U.S. locations
1
States / cities
Bennettsville, South Carolina
Source: ClinicalTrials.gov public record
Updated Mar 1, 2018 · Synced Sep 8, 2026, 11:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Bioequivalence of Dapagliflozin/Metformin XR Fixed-dose Combination Tablets in Healthy Subjects

NCT02637037
View directory record Official record
Conditions
Bioequivalence, Fixed Dose Combination Tablets, Healthy Male and Female Subjects
Interventions
dapagliflozin/metformin XR 5/500 mg test drug (Mount Vernon), dapagliflozin/metformin XR 5/500 mg reference drug (Humacao), dapagliflozin/metformin XR 10/1000 mg test drug (Mount Vernon), dapagliflozin/metformin XR 10/1000 mg reference drug (Humacao)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
80 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 12, 2018 · Synced Sep 8, 2026, 11:02 AM EDT
Completed No phase listed Observational Results available

Second-line Therapies for Patients With Type 2 Diabetes and Moderate Cardiovascular Disease Risk

NCT05214573
View directory record Official record
Conditions
Type 2 Diabetes, Cardiac Disease
Interventions
Glucagon like peptide 1 receptor agonist, Sodium-glucose cotransporter 2 inhibitor, Dipeptidyl Peptidase 4 Inhibitor, Sulfonylurea
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
21 Years and older
Enrollment
386,301 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Sep 8, 2026, 11:02 AM EDT
Completed Phase 3 Interventional Results available

A Study to Compare the Glycemic Effects, Safety, and Tolerability of Exenatide Once Weekly to Those of Sitagliptin and Pioglitazone,in Subjects With Type 2 Diabetes Treated With Metformin (DURATION - 2)

NCT00637273
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
exenatide once weekly, sitagliptin, pioglitazone, placebo tablet, placebo once weekly
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
514 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
51
States / cities
Peoria, Arizona • Artesia, California • Concord, California + 48 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2015 · Synced Sep 8, 2026, 11:02 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Targeting the Endothelial Glycocalyx to Enhance Vascular Function and Exercise-Induced Vascular Adaptations in Type 2 Diabetes

NCT05205005
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Endocalyx, Placebo
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
45 Years to 64 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated May 1, 2025 · Synced Sep 8, 2026, 11:02 AM EDT
Not listed Phase 3 Interventional

Efficacy Study of High Dose Symlin to Treat Type 2 Diabetes Mellitus

NCT01137695
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Pramlintide
Drug
Lead sponsor
Cheryl Rosenfeld, DO
Other
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Denville, New Jersey • Staten Island, New York • Langhorne, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 13, 2011 · Synced Sep 8, 2026, 11:02 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

RISE Pediatric Medication Study

NCT01779375
View directory record Official record
Conditions
Prediabetes, Type 2 Diabetes
Interventions
Metformin, Glargine
Drug
Lead sponsor
RISE Study Group
Network
Eligibility
10 Years to 19 Years
Enrollment
91 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
4
States / cities
Denver, Colorado • New Haven, Connecticut • Indianapolis, Indiana + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2023 · Synced Sep 8, 2026, 11:02 AM EDT
Recruiting No phase listed Observational

Gut Microbiota in Metabolic Surgery

NCT05000996
View directory record Official record
Conditions
Bariatric Surgery Candidate, Cardiovascular Diseases, Type 2 Diabetes, Dyslipidemias, Hypertension, Morbid Obesity
Interventions
Bariatric Surgery
Procedure
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
21 Years to 65 Years
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2035
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 3, 2025 · Synced Sep 8, 2026, 11:02 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Research Study Looking at the Comparability of 2 Different Forms of Oral Semaglutide in Healthy People

NCT05227196
View directory record Official record
Conditions
Healthy Volunteers, Type 2 Diabetes
Interventions
Semaglutide D Dose 1, Semaglutide D Dose 2, Semaglutide D Dose 3, Semaglutide Dose 4, Semaglutide Dose 5, Semaglutide Dose 6
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years to 64 Years
Enrollment
546 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
Cypress, California • Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 18, 2024 · Synced Sep 8, 2026, 11:02 AM EDT
Completed Phase 4 Interventional Results available

A Study of the Effects of Canagliflozin (JNJ-28431754) on Renal Endpoints in Adult Participants With Type 2 Diabetes Mellitus

NCT01989754
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Albuminuria
Interventions
Placebo, Canagliflozin, 100 mg, Canagliflozin, 300 mg
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
30 Years and older
Enrollment
5,813 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
57
States / cities
Little Rock, Arkansas • Carmichael, California • Concord, California + 54 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2018 · Synced Sep 8, 2026, 11:02 AM EDT
Completed Phase 1 Interventional Results available

Safety, Tolerability and Pharmacokinetics Study of EGT0001474 in Subjects With Type 2 Diabetes

NCT00924053
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
EGT0001474, Placebo
Drug
Lead sponsor
Theracos
Industry
Eligibility
18 Years to 70 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Jun 16, 2019 · Synced Sep 8, 2026, 11:02 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Sugar Challenge Study

NCT04621656
View directory record Official record
Conditions
Type 2 Diabetes, Pre-Diabetes, Healthy
Interventions
January Mobile Application (Sugar AI)
Combination Product
Lead sponsor
January, Inc.
Industry
Eligibility
18 Years to 75 Years
Enrollment
1,022 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2021
U.S. locations
1
States / cities
Menlo Park, California
Source: ClinicalTrials.gov public record
Updated Nov 8, 2020 · Synced Sep 8, 2026, 11:02 AM EDT
Enrolling by invitation Phase 4 Interventional

Evaluate the Efficacy of an Oral Health Behavioral Intervention in People With Diabetes

NCT07619729
View directory record Official record
Conditions
Diabetes Type 2, Periodontal Disease, Caries
Interventions
Diabetes Oral Health Program, Stannous Fluoride Dentifrice, Cetylpyridinium Chloride (CPC) and Zinc Lactate Mouthwash
Behavioral · Drug
Lead sponsor
Colgate Palmolive
Industry
Eligibility
18 Years and older
Enrollment
10,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Long Island City, New York
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 8, 2026, 11:02 AM EDT